Policy on use of unlicensed medicines, policy for informed consent for use of unlicensed medicines, board level roles responsible for patient safety and consent, policy for use of compounded avastin (bevacizumab) for treatment of wet age related macular degeneration

FOI reference number: FOI2019/0233

FOI request subject:

Response Document

Requestor details: Private company

Total / Partial release: Total Release

Answered on 21/08/2019